ORTHOCELL LTD's stock soared 7.84% during intraday trading on Friday.
The surge followed the company's announcement that the first surgical case using its nerve repair product, Remplir, has been completed at a military base hospital within the US Department of Defense/Veterans Affairs hospital network. This milestone represents a significant step in Orthocell's US commercialization strategy for the product.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.